Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis.

Files

hdl_145029.pdf (318.52 KB)
  (Published version)

Date

2024

Authors

Murray, G.M.
Griffith, N.
Sinnappurajar, P.
Al Julandani, D.A.
Clarke, S.L.N.
Hawley, D.P.
Choi, J.
Guly, C.M.
Ramanan, A.V.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Ocular Immunology and Inflammation, 2024; 32(4):442-446

Statement of Responsibility

G. M. Murray, N. Griffith, P. Sinnappurajar, D. A. Al Julandani, S. L. N. Clarke, D. P. Hawley, J. Choi, C. M. Guly, Athimalaipet V. Ramanan

Conference Name

Abstract

Background: Adalimumab has demonstrated efficacy in non-infectious uveitis. With the introduction of biosimilar agents such as Amgevita, we aimed to quantify efficacy and tolerability compared to Humira in a multi-centre UK cohort Methods: Patients identified from tertiary uveitis clinics in 3 centres, after institution-mandated switching was implemented. Results: Data collected for 102 patients, aged 2–75 years, with 185 active eyes. Following switch, rates of uveitis flare were not significantly different (13 events before, 21 after, p = .132). Rates of elevated intraocular pressure were decreased (32 before, 25 afterwards, p = .006) and dosing of oral and intra-ocular steroids was stable. Twenty-four patients (24%) requested to return to Humira, commonly due to pain from injection or technical difficulty with the device. Conclusion: Amgevita is safe and effective for inflammatory uveitis with non-inferiority to Humira. Significant numbers of patients requested to switch back due to side effects including injection site reactions.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

© 2023 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

License

Grant ID

Call number

Persistent link to this record